| Expression pattern: |
DN |
| Associated gene: |
QKI-5, Notch intracellular domain (NICD), HES1, Hey2 |
| Associated microRNA: |
miR-17 |
| Biological function: |
circ-MTO1 suppresses LUAD cell proliferation and tumor growth, acts as a tumor suppressor, and is associated with advanced clinical stage, lymph node metastasis, and prognosis. |
| Molecular mechanism: |
circ-MTO1 sponges miR-17 to increase QKI-5 expression, which inactivates the Notch signaling pathway; QKI-5 also promotes circ-MTO1 expression, forming a circ-MTO1/miR-17/QKI-5 feedback loop. |
| Biological pathway or process: |
Notch (inhibits); proliferation (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Luciferase Reporter Assay; RNA Pull-Down; Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Low circ-MTO1 expression is associated with advanced clinical stage, lymph node metastasis, shorter overall survival, and shorter progression-free survival; endogenous circ-MTO1 is a promising prognostic predictor for LUAD patients. |
| Description: |
circ-MTO1 is down-regulated in LUAD and functions as a tumor suppressor by inhibiting LUAD cell proliferation and xenograft tumor growth. Mechanistically, it sponges miR-17 to increase QKI-5 expression and inactivate Notch signaling, while QKI-5 can promote circ-MTO1 expression to form a feedback loop. Clinically, low circ-MTO1 expression is associated with advanced disease features and poorer overall and progression-free survival. |
| Confidence score: |
0.7878 |